{"id":26197,"date":"2025-04-17T21:24:51","date_gmt":"2025-04-17T21:24:51","guid":{"rendered":"https:\/\/medexperts.pro\/?p=26197"},"modified":"2025-04-17T21:31:59","modified_gmt":"2025-04-17T21:31:59","slug":"what-to-know-about-eli-lillys-daily-pill-for-weight-loss","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=26197","title":{"rendered":"What to Know About Eli Lilly\u2019s Daily Pill for Weight Loss"},"content":{"rendered":"<div><\/div>\n<p id=\"article-summary\" class=\"css-79rysd e1wiw3jv0\">Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.<\/p>\n<section class=\"meteredContent css-1r7ky0e\">\n<div class=\"css-s99gbd StoryBodyCompanionColumn\" data-testid=\"companionColumn-0\">\n<div class=\"css-53u6y8\">\n<p class=\"css-at9mc1 evys1bk0\">Encouraging <a class=\"css-yywogo\" href=\"https:\/\/www.nytimes.com\/2025\/04\/17\/health\/pill-glp-1-eli-lilly.html\" title>clinical trial results<\/a> announced on Thursday stand to open up a huge market for a convenient daily pill to treat obesity and diabetes.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">The experimental drug, developed by Eli Lilly and known as orforglipron, is a type of medication known as a GLP-1. Drugs in this class like Wegovy have become hugely popular because they help people lose weight.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">But those drugs must be given as weekly injections, which has limited their use. If orforglipron can deliver similar results in an easy-to-take pill form, as the study suggested it could, it has the potential to reach many more patients and become a major blockbuster.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Here\u2019s what to know about Eli Lilly\u2019s pill, which still must go through a review process by the Food and Drug Administration to be approved for sale.<\/p>\n<\/div>\n<\/div>\n<div data-testid=\"Dropzone-1\"><\/div>\n<div class=\"css-s99gbd StoryBodyCompanionColumn\" data-testid=\"companionColumn-1\">\n<div class=\"css-53u6y8\">\n<h2 class=\"css-13o6u42 eoo0vm40\" id=\"link-e22749b\">When will the pill become available?<\/h2>\n<p class=\"css-at9mc1 evys1bk0\">Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to review the company\u2019s trial data before making a decision.<\/p>\n<p class=\"css-at9mc1 evys1bk0\">Wall Street analysts said that if all went smoothly, orforglipron could become available in the United States sometime in the second half of next year.<\/p>\n<div class=\"css-kbghgg\">\n<div class=\"css-121kum4\">\n<div class=\"css-171quhb\"><\/div>\n<div class=\"css-asuuk5\">\n<div class=\"css-7axq9l\" data-testid=\"optimistic-truncator-noscript\">\n<div data-testid=\"optimistic-truncator-noscript-message\" class=\"css-6yo1no\">\n<p class=\"css-3kpklk\">We are having trouble retrieving the article content.<\/p>\n<p class=\"css-3kpklk\">Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n<div class=\"css-1dv1kvn\" id=\"optimistic-truncator-a11y\">\n<hr \/>\n<p>Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0<a href=\"https:\/\/myaccount.nytimes.com\/auth\/login?response_type=cookie&amp;client_id=vi&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2025%2F04%2F17%2Fhealth%2Fweight-loss-pill-eli-lilly.html&amp;asset=opttrunc\">log into<\/a>\u00a0your Times account, or\u00a0<a href=\"https:\/\/www.nytimes.com\/subscription?campaignId=89WYR&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2025%2F04%2F17%2Fhealth%2Fweight-loss-pill-eli-lilly.html\">subscribe<\/a>\u00a0for all of The Times.<\/p>\n<hr \/>\n<\/div>\n<div class=\"css-1g71tqy\">\n<div data-testid=\"optimistic-truncator-message\" class=\"css-6yo1no\">\n<p class=\"css-3kpklk\">Thank you for your patience while we verify access.<\/p>\n<p class=\"css-3kpklk\">Already a subscriber?\u00a0<a data-testid=\"log-in-link\" class=\"css-z5ryv4\" href=\"https:\/\/myaccount.nytimes.com\/auth\/login?response_type=cookie&amp;client_id=vi&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2025%2F04%2F17%2Fhealth%2Fweight-loss-pill-eli-lilly.html&amp;asset=opttrunc\">Log in<\/a>.<\/p>\n<p class=\"css-3kpklk\">Want all of The Times?\u00a0<a data-testid=\"subscribe-link\" class=\"css-z5ryv4\" href=\"https:\/\/www.nytimes.com\/subscription?campaignId=89WYR&amp;redirect_uri=https%3A%2F%2Fwww.nytimes.com%2F2025%2F04%2F17%2Fhealth%2Fweight-loss-pill-eli-lilly.html\">Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.Encouraging clinical trial results announced on Thursday stand to open up a huge market for a convenient daily pill to treat obesity and diabetes.The experimental drug, developed by Eli Lilly and known as orforglipron, is a type of medication known as a GLP-1. Drugs in this class like Wegovy have become hugely popular because they help people lose weight.But those drugs must be given as weekly injections, which has limited their use. If orforglipron can deliver similar results in an easy-to-take pill form, as the study suggested it could, it has the potential to reach many more patients and become a major blockbuster.Here\u2019s what to know about Eli Lilly\u2019s pill, which still must go through a review process by the Food and Drug Administration to be approved for sale.When will the pill become available?Eli Lilly said that it planned to seek regulatory approval to market the drug for weight loss later this year, and early next year for diabetes. The F.DA. could take months and possibly longer to review the company\u2019s trial data before making a decision.Wall Street analysts said that if all went smoothly, orforglipron could become available in the United States sometime in the second half of next year.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":26199,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-26197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26197"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26197\/revisions"}],"predecessor-version":[{"id":26200,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/26197\/revisions\/26200"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/26199"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}